par pharmaceutical

Acorda Therapeutics Inc (NASDAQ: ACOR) accused one of its rivals, Par Pharmaceutical, of infringing patents related to its multiple sclerosis treatment drug called Ampyra (dalfampridine) back in September, 2015. Par Pharmaceutical was seeking marketing approval from the FDA for its generic...

Endo International plc (NASDAQ: ENDP) will buy Par Pharmaceutical from TPG Capital for $1.5 billion in stock and $6.5 billion in cash, the companies announced. Endo was up more than 1 percent in pre-market trading on news of the deal, which will create one of the top five generic drug...

Goldman Sachs says that it is only modestly tweaking its Par Pharmaceutical (NYSE: PRX) estimates “following the quarter despite the miss, assuming that higher spending will not repeat going forward with operating expenses falling broadly in line with management's 3-year guidance.” “Continued slow...

UBS has initiated coverage for the following companies: Par Pharmaceutical Companies (NYSE: PRX) Buy, $35 price target Alkermes Inc. (NASDAQ: ALKS) Buy, $18 price target